<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008163</url>
  </required_header>
  <id_info>
    <org_study_id>YY351-1</org_study_id>
    <secondary_id>YY-351-4</secondary_id>
    <nct_id>NCT01008163</nct_id>
  </id_info>
  <brief_title>A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase Ⅱ, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Efficacy and Safety of YY-351 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuyu Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuyu Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the dosage selected and to evaluate the efficacy
      and safety of YY-351.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ginseng has been widely studied for treatment of diabetes, dyslipidemia and obesity.
      Interestingly, in addition to ginseng root, ginseng berry and leaf were also shown to reduce
      blood glucose in diabetic models. In our recent study, ginsam, vinegar extraction from Panax
      ginseng, which is enriched in the ginsenoside Rg3, has distinct beneficial effects on glucose
      metabolism and body weight control in an obese animal model of insulin resistance by changing
      the expression of genes involved in glucose and fatty acid metabolism. Our group has also
      published that Rg3 improves insulin signaling and glucose uptake primarily by stimulating the
      expression of IRS-1 and GLUT4. Thus, we have evaluated the efficacy, dose-response
      relationships and safety of a ginsam, a vinegar extract from Panax ginseng.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the fasting plasma glucose and postprandial glucose [after 2 hours, oral glucose tolerance test (OGTT) (75 g)] and HbA1c</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects achieving a glycemic response defined as ≤ 7.0%</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of HbA1c &gt; 0.5%</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers [liver function tests (LFT), high-sensitivity C-reactive protein (hsCRP), adiponectin]</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (or body composition)</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist girth</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment (HOMA)</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-351, PO, 1T tid. / Placebo, 1T tid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-351. PO, 2T bid. / Placebo 2T qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-351, PO, 2T tid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, PO, 2T tid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-351/Placebo</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ginsam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-351/Placebo</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ginsam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-351</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Ginsam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous diagnosis of Type 2 diabetes(more than 3months)

          -  Patients aged over 18 years

          -  FPG levels in the range : 126 - 270mg/dL or HbA1c : 7.0 - 12.0%

        Exclusion Criteria:

          -  Pregnant women, Breast feeding, or actively trying to be come pregnant

          -  Patients with Type 1 DM, gestational diabetes or secondary diabetes

          -  FPG levels in the range : ≥ 270mg/dL HbA1c : ＜ 7.0, ＞12.0%

          -  Patient who take the medicine which may affect to blood sugar control (i.e.systemic
             glucocorticoid)

          -  Patients with diabetic complications or the history of a case that would affect to
             efficacy and safety evaluation (i.e. Thyroid disorder, Cushing's Syndrome, Multiple
             ovarian cystoma, pheochromocytoma)

          -  Patients with Chronic hepatitis, hepatitis B, C (except healthy HBV carrier) or Liver
             diseases (AST or/and ALT &gt;2 × ULN(upper limit normal))

          -  Patients with Kidney disorder (Cr&gt;2.0)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>300 Gumi-Dong, Bungdang-Gu</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <last_update_submitted>November 3, 2009</last_update_submitted>
  <last_update_submitted_qc>November 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Seoul National University Bundang Hospital</name_title>
    <organization>Department of Internal Medicine</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

